EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies

I-Chung Chen, Hong-Yi Lin, Zheng-Yang Liu, Wei-Jie Cheng, Tzu-Yi Yeh, Wen-Bin Yang, Hoang Yen Tran, Mei-Jung Lai, Chung-Han Wang, Tzu-Yuan Kao, Chia-Yang Hung, Ya-Lin Huang und 4 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c02086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von I-Chung Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan. Hauptthemen laut MEDLINE: Glioblastoma, Histone Deacetylase Inhibitors, Drug Repositioning, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Ministry of Education, Taiwan, Sunny Brain Tumor and Brain Disease Research and Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since decades after temozolomide was approved, no effective drugs have been developed. Undoubtedly, blood-brain barrier (BBB) penetration is a severe issue that should be overcome in glioblastoma multiforme (GBM) drug development. In this research, we were inspired by linezolid through structural modification with several bioactive moieties to achieve the desired brain delivery. The results indicated that the histone deacetylase modification, referred to as compound 1, demonstrated promising cytotoxic effects in various brain tumor cell lines. Further comprehensive mechanism studies indicated that compound 1 induced acetylation, leading to DNA double-strand breaks, and induced the ubiquitination of RAD51, disrupting the DNA repair process. Furthermore, compound 1 also exhibited dramatic improvement in the orthotopic GBM mouse model, demonstrating its efficacy and satisfying BBB penetration. Therefore, the reported compound 1, provided with an independent therapeutic pathway, satisfying elongation in survival and tumor size reduction, and the ability to penetrate the BBB, was potent to achieve further development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHistone Deacetylase InhibitorsDrug RepositioningBrain NeoplasmsLinezolidHumansAnimalsMiceCell Line, TumorAntineoplastic AgentsBlood-Brain BarrierMice, NudeRad51 RecombinaseCell ProliferationAcetylation

Substanzen

Histone Deacetylase InhibitorsLinezolidAntineoplastic AgentsRad51 Recombinase

Autor:innen und Institutionen

  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 110, Taiwan.
  • Taipei Neuroscience Institute, New Taipei City 235, Taiwan.
  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
  • Taiwan Brain Disease Foundation, Taipei 100, Taiwan.
  • TMU Research Center for Drug Discovery, Taipei Medical University, Taipei 110, Taiwan.
  • Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan.

ORCID-Profile: Tsung-I Hsu, Jing-Ping Liou

Förderung

  • National Science and Technology Council
  • Ministry of Education, Taiwan
  • Sunny Brain Tumor and Brain Disease Research and Development Fund

Zitieren

APA

Chen, I. C., Lin, H. Y., Liu, Z. Y., Cheng, W. J., Yeh, T. Y., Yang, W. B., Tran, H. Y., Lai, M. J., Wang, C. H., Kao, T. Y., Hung, C. Y., Huang, Y. L., Liou, K. C., Hsieh, C. M., Hsu, T. I., & Liou, J. P. (2025). Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02086

Vancouver

Chen IC, Lin HY, Liu ZY, Cheng WJ, Yeh TY, Yang WB, et al. Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02086

BibTeX
@article{Chen2025,
  author = {Chen, I-Chung and Lin, Hong-Yi and Liu, Zheng-Yang and Cheng, Wei-Jie and Yeh, Tzu-Yi and Yang, Wen-Bin and Tran, Hoang Yen and Lai, Mei-Jung and Wang, Chung-Han and Kao, Tzu-Yuan and Hung, Chia-Yang and Huang, Ya-Lin and Liou, Ke-Chi and Hsieh, Chien-Ming and Hsu, Tsung-I and Liou, Jing-Ping},
  title = {Repurposing Linezolid in Conjunction with Histone Deacetylase Inhibitor Access in the Realm of Glioblastoma Therapies},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c02086}
}
Kostenlos starten →